Médecine

Paramédical

Autres domaines


S'abonner

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies - 18/12/13

Doi : 10.1016/j.jaad.2013.09.020 
Jeremy Hugh, MD a, Abby S. Van Voorhees, MD b, Rajiv I. Nijhawan, MD a, Jerry Bagel, MD c, Mark Lebwohl, MD d, Andrew Blauvelt, MD e, Sylvia Hsu, MD f, Jeffrey M. Weinberg, MD a,
a Department of Dermatology, St Luke’s-Roosevelt Hospital Center, New York, New York 
b Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 
c Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey 
d Department of Dermatology, Mount Sinai School of Medicine, New York, New York 
e Oregon Medical Research Center, Portland, Oregon 
f Department of Dermatology, Baylor College of Medicine, Houston, Texas 

Reprint requests: Jeffrey M. Weinberg, MD, Department of Dermatology, St Luke’s-Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025.

Abstract

Background

Many studies have identified cardiovascular risk factors in patients with psoriasis. Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD.

Objective

We reviewed the literature to define the impact of common psoriasis therapies on cardiovascular measures and outcomes.

Results

Phototherapy has no major cardiovascular impact and may reduce levels of proinflammatory cytokines. Acitretin increases serum lipids and triglycerides, but has not been shown to increase cardiovascular risk. Cyclosporine A increases blood pressure, serum triglycerides, and total cholesterol. Methotrexate is associated with a decreased risk of CVD morbidity and mortality. Among the biologics, data for tumor necrosis factor inhibitors suggest an overall reduction in cardiovascular events. Most data on short-term ustekinumab use suggest no effect on major adverse cardiovascular events, however some authorities remain concerned. Nevertheless, ustekinumab use over a 4-year period shows a decrease in major adverse cardiovascular events when compared both with the general US population and with psoriatics in Great Britain.

Limitations

Most studies lack the power and randomization of large clinical trials and long-term follow-up periods. In addition, the increased risk of CVD associated with psoriasis itself is a confounding factor.

Conclusion

Some therapies for moderate to severe psoriasis, including methotrexate and tumor necrosis factor inhibitors, may reduce cardiovascular events in psoriatic patients. Ustekinumab appears to be neutral but there may be a long-term benefit. Appropriate patient counseling and selection and clinical follow-up are necessary to maximize safety with these agents. Further long-term study is necessary to quantify the benefits and risks associated with biologic therapies.

Le texte complet de cet article est disponible en PDF.

Key words : adalimumab, biologic therapies, cardiovascular, cyclosporine, etanercept, infliximab, methotrexate, mycophenolate mofetil, psoralen plus ultraviolet A, psoriasis, ultraviolet therapy, ustekinumab

Abbreviations used : CHF, CVD, DM, HTN, IL, MACE, MI, MTX, PsA, PUVA, RA, TNF, TNFi, UV, VEGF


Plan


 Funding sources: None.
 Disclosure: Dr Van Voorhees has served on advisory boards for Amgen, Abbott Laboratories, Genentech, Novartis, Warner Chilcott, Centocor/Janssen Biotech, and LEO Pharma; has been an investigator and consultant for Amgen; and has been a speaker for Amgen, Abbott Laboratories, and Centocor/Janssen Biotech. Dr Bagel has served as consultant, on advisory boards, and as a speaker and investigator for Amgen and Abbott Laboratories. Dr Lebwohl has served as consultant and investigator for Abbott Laboratories, Amgen, Celgene, Eli Lilly & Co, Janssen Biotech, and LEO Pharma; as an investigator for Ranbaxy; and as a consultant for Anacor Pharmaceuticals, BioLineRX, Dermipsor, Galderma, GlaxoSmithKline-Stiefel, Maruho, Novartis, Pfizer, and Valeant. Dr Blauvelt has served on advisory boards and as investigator and consultant for Janssen Biotech, Novartis, and Eli Lilly & Co; as a speaker for Janssen Biotech; and as an investigator for Abbott Laboratories, Amgen, and Celgene. Dr Hsu has served on advisory boards for Abbott Laboratories, Amgen, Biogen Idec, Centocor/Janssen Biotech, and Genentech; and has been an investigator for Centocor/Janssen Biotech. Dr Weinberg has served as a speaker for Abbott Laboratories, Amgen, and Genentech, and has performed clinical research for Amgen, Celgene, and Janssen Biotech. Drs Hugh and Nijhawan have no conflicts of interest to declare.


© 2013  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 70 - N° 1

P. 168-177 - janvier 2014 Retour au numéro
Article précédent Article précédent
  • Research gaps in psoriasis: Opportunities for future studies
  • Caitriona Ryan, Neil J. Korman, Joel M. Gelfand, Henry W. Lim, Craig A. Elmets, Steven R. Feldman, Alice B. Gottlieb, John Y.M. Koo, Mark Lebwohl, Craig L. Leonardi, Abby S. Van Voorhees, Reva Bhushan, Alan Menter
| Article suivant Article suivant
  • From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti–tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis
  • Kiran Motaparthi, Vladimir Stanisic, Abby S. Van Voorhees, Mark G. Lebwohl, Sylvia Hsu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.